Cargando…
单中心晚期非小细胞肺癌免疫治疗真实世界数据分析
BACKGROUND AND OBJECTIVE: In recent years, a number of clinical trials have shown that immunocheckpoint inhibitors (ICI) have brought survival benefits to patients with advanced non-small cell lung cancer (NSCLC), however, such clinical trials comprise cohorts selected based on strict and complex en...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885419/ https://www.ncbi.nlm.nih.gov/pubmed/31771737 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.11.02 |
Ejemplares similares
-
EGFR突变晚期非小细胞肺癌患者后线接受免疫治疗的疗效分析
Publicado: (2021) -
LIPI及iSEND免疫评分在晚期非小细胞肺癌免疫治疗中的预测价值分析
Publicado: (2022) -
非小细胞肺癌腹膜转移预后因素的单中心回顾性分析
Publicado: (2019) -
双药方案对比单药方案治疗老年晚期非小细胞肺癌的Meta分析
Publicado: (2012) -
ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析
Publicado: (2020)